Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

N/A

5(71.4%)

Early Phase 1

1(14.3%)

Phase 2

1(14.3%)

7Total

N/A(5)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07473817Not Yet Recruiting

Validation of Different Methods for HepQuant DuO® Blood Sample Collection

Role: lead

NCT07009132Recruiting

Cholate Clearance in Fontan and Heart Failure

Role: lead

NCT06899152Not ApplicableRecruiting

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

Role: collaborator

NCT07060547Recruiting

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

Role: lead

NCT03583996Not ApplicableCompleted

The SHUNT-V Study for Varices

Role: lead

NCT06144827Not ApplicableWithdrawn

A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer

Role: collaborator

NCT04664621Not ApplicableWithdrawn

HepQuant to Predict Hepatic Encephalopathy After TIPS

Role: collaborator

NCT03087968Early Phase 1Withdrawn

Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Role: lead

NCT03294941Phase 2Terminated

The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology

Role: lead

NCT01579162Not ApplicableCompleted

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

Role: lead

All 10 trials loaded